Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 11/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669421 | 0.99 | HPGDS (0.57) | HPGDSABCB1CYP2D6CCR6L3MBTL1 | |
| SCHEMBL11891931 | 0.88 | HPGDS (0.46) | HPGDSL3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL18155190 | 0.86 | HPGDS (0.58) | HPGDSABCB1CYP2D6CCR6L3MBTL1 | |
| SCHEMBL20614674 | 0.85 | HPGDS (0.57) | HPGDSABCB1CYP2D6CCR6L3MBTL1 | |
| SCHEMBL28509888 | 0.82 | HDAC6 (0.56) | HDAC6HDAC1HDAC5 | |
| Hydrochloric Acid SCHEMBL6565113 | 0.79 | L3MBTL1 (0.68) | L3MBTL1MEN1NPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL20599057 | 0.78 | HPGDS (0.52) | HPGDSABCB1CYP2D6CCR6L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11032862 | 0.78 | HPGDS (0.52) | HPGDSABCB1CYP2D6CCR6L3MBTL1 | |
| Hydrochloric Acid SCHEMBL19206937 | 0.78 | HPGDS (0.52) | HPGDSABCB1CYP2D6CCR6L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11025587 | 0.78 | HPGDS (0.52) | HPGDSABCB1CYP2D6CCR6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2021-10-28 | — | — | US | disclosed |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2020-12-10 | — | — | US | disclosed |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-08-29 | — | — | US | disclosed |
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-01-03 | — | — | US | disclosed |
| US-9937175-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2018-04-10 | — | — | US | disclosed |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI- AVENTIS (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9469627-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2016-10-18 | — | — | US | disclosed |
| EP-2486024-B1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| CN-102666508-A | Phenyl oxadiazole derivatives as prostaglandin D synthase inhibitors | SANOFI AVENTIS | 2012-09-12 | — | — | CN | disclosed |
| EP-2486024-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-07-26 | — | — | US | disclosed |
| WO-2011044307-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HDAC6 842/4885HDAC1 1199/4885HDAC5 982/4885 |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HDAC6 842/4885HDAC1 1199/4885HDAC5 982/4885 |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HDAC6 856/4885HDAC1 1152/4885HDAC5 937/4885 |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HDAC6 842/4885HDAC1 1199/4885HDAC5 982/4885 |
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HDAC6 842/4885HDAC1 1199/4885HDAC5 982/4885 |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HDAC6 846/4885HDAC1 1134/4885HDAC5 995/4885 |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HDAC6 842/4885HDAC1 1199/4885HDAC5 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.